Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

"The new results show that the 3-step method now used produces fewer insignificant cancer diagnoses than PSA screening,” says Anssi Auvinen, MD, PhD.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

Among the patients who were on treatment for 12 weeks or less, treatment interruptions due to TEAEs occurred in 12.6% of patients, and discontinuations due to TEAEs occurred in 5.3% patients.